Company news

Orum Therapeutics, Inc. news in 2026

Orum Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Orum Therapeutics Announces U.S. FDA Clearance of an IND Application for ORM-1153, a Novel CD123-GSPT1 Degrader-Antibody Conjugate

August 22, 2026

Orum Therapeutics Appoints Dr. Maria Koehler and Geoff Meyerson to Board of Directors

April 13, 2026

Orum Therapeutics to Present New Preclinical Data on ORM-1153, a CD123-Targeting Degrader Antibody Conjugate, at the AACR Annual Meeting 2026

March 17, 2026

Decks in 2026